ArticleWorld journal of surgical oncology2025
The correlation between EGFR mutation status and clinicopathological characteristics, Ki67 expression and immune cell infiltration in lung adenocarcinoma with different radiological subtypes.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk prediction of non-small cell lung cancer in patients with pulmonary nodules: a single-center cohort study based on six machine learning algorithms.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo clearly reveal the correlations between epidermal growth factor receptor (EGFR) mutation status and clinicopathological characteristics, Ki67 expression and immune cell Infiltration in lung adenocarcinoma (LUAD) with different radiological subtypes.
methodsPatients with pathological stage 0-III LUAD who underwent resection and received EGFR detection in our department between July 2019 and May 2023 were retrospectively reviewed. All included patients were divided into four groups based on different consolidation-to-tumour ratio (CTR). Tumors without ground glass opacity (GGO) component were defined as solid nodule featured LUAD (SN-LUAD, CTR = 1) and the other tumors with GGO were defined as GGO featured LUAD (GGO-LUAD, 0 ≤ CTR < 1). The clinicopathological characteristics, Ki67 expression, immune cell infiltration and EGFR mutation status were compared between diferent CTR groups.
resultsA total of 544 patients were finally included, 140 in the pure GGO group (PGGO, CTR = 0), 120 in the GGO-dominant group (GGO-D, 0 < CTR ≤ 0.5), 92 in the SN-dominant group (SN-D, 0.5 < CTR < 1), and 192 in the pure solid nodule group (SN, CTR = 1). The rate of EGFR mutations were significantly more higher in elderly patients (P < 0.001), well/moderate differentiated (P < 0.001), invasive (P < 0.001) and large size tumors (P < 0.001). Regardless of gender, smoking status, tumor size, and pathological subtype, the rate of EGFR mutation in GGO-LUAD significantly increases with the decrease of GGO component. Importantly, the expression of Ki67 was significantly correlated with EGFR mutation status in GGO-LUAD, but not in SN-LUAD. In GGO-LUAD, tumors with EGFR mutations have significantly higher Ki67 expression than tumors without. Additionally, SN-LUAD has significantly higher infiltration of tumor associated macrophages and regulatory T cells compared to GGO-LUAD in EGFR mutated LUAD.
conclusionsEGFR mutation rates vary by clinicopathological characteristics and EGFR mutation status significantly influence tumor proliferation and immune cell infiltration in LUAD across radiological subtypes. These findings not only indicate that EGFR mutations may play a crucial role in the progression of GGO-LUAD, but also explain why GGO-LUAD has a better prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.